Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages 789-796

  Pardanani, Animesh ^a   Gotlib, Jason R ^a   Jamieson, Catriona ^a   Cortes, Jorge E ^a   Talpaz, Moshe ^a   Stone, Richard M ^a   Silverman, Michael H ^a   Gilliland, D Gary ^a   Shorr, Jolene ^a   Tefferi, Ayalew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; CYTOKINE; JANUS KINASE 2 INHIBITOR; STAT PROTEIN; TG 101348; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPERAMYLASEMIA; HYPERLIPASEMIA; HYPOCALCEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; SATIETY; SIDE EFFECT; SKIN EXFOLIATION; SPLEEN; SPLEEN SIZE; SYMPTOM; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 2; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PYRROLIDINES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952333359     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8021     Document Type: Article

References (26)

1. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
2. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-2901, 2009
3. Hussein K, Pardanani AD, Van Dyke DL, et al: International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 115:496-499, 2010
4. Patnaik MM, Caramazza D, Gangat N, et al: Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 84:105-108, 2010
5. James C, Ugo V, Le Couédic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148, 2005 (Pubitemid 40663494)
6. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468, 2007 (Pubitemid 46193073)
7. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270, 2006
8. Delhommeau F, Dupont S, Della Valle V, et al: Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301, 2009
9. Carbuccia N, Murati A, Trouplin V, et al: Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183-2186, 2009
10. Green A, Beer P: Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:369-370, 2010
11. Tefferi A, Lasho TL, Abdel-Wahab O, et al: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24:1302-1309, 2010
12. Grand FH, Hidalgo-Curtis CE, Ernst T, et al: Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113:6182-6192, 2009
13. Jäger R, Gisslinger H, Passamonti F, et al: Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24:1290-1298, 2010
14. Oh ST, Simonds EF, Jones C, et al: Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116:988-992, 2010
15. Ernst T, Chase AJ, Score J, et al: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722-726,
16. Lasho TL, Tefferi A, Hood JD, et al: TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 22:1790-1792, 2008
17. Geron I, Abrahamsson AE, Barroga CF, et al: Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13:321-330, 2008 (Pubitemid 351446196)
18. Wernig G, Kharas MG, Okabe R, et al: Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311-320, 2008 (Pubitemid 351446195)
19. Mullally A, Lane SW, Ball B, et al: Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17:584-596, 2010
20. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22, 2008
21. Tefferi A, Barosi G, Mesa RA, et al: International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497-1503, 2006
22. Kittur J, Knudson RA, Lasho TL, et al: Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109:2279-2284, 2007 (Pubitemid 46801558)
23. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 108:3472-3476, 2006
24. Oh ST, Simonds EF, Jones C, et al: Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood doi:10.1182/blood.2010.02.270108 [epub on April 19, 2010]
25. Pardanani A, Lasho TL, Finke C: LNK mutations studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2, and MPL mutations. Leukemia 24:1713-1718, 2010
26. Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007 (Pubitemid 350159618)